NCT07392892
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 14, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 100 → 124 locations
- Minor Primary completion moved earlier from Jan 15, 2032 to Jul 22, 2031
- Study completion moved earlier from Jan 14, 2033 to Jul 21, 2032
- Minor Study sites: 100 to 102
Notable Eligibility criteria expanded, about 15 words Show 4 more changesShow less
- Primary completion pushed from Jul 22, 2031 to Jan 15, 2032
- Trial sites expanded: 74 → 100 locations
- Study completion pushed from Jul 21, 2032 to Jan 14, 2033
- Secondary endpoints: details revised at 2 of 19 entries
- Minor Trial sites expanded: 70 → 74 locationsv6
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 69 to 70v5
- Minor Study sites: 71 to 69v4
- Minor Trial sites expanded: 58 → 71 locations
- Start date changed from estimate of Apr 28, 2026 to May 14, 2026
- Study title expanded, about 1 word
- Notable Recruitment opened
- Start date: Mar 2, 2026 to Apr 28, 2026
- Eligibility criteria expanded, about 14 words
- Trial sites expanded: 0 → 58 locations
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Timeframe: Approximately 4 years
Phase 2: Number of participants with treatment-emergent adverse events
Timeframe: Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Timeframe: Approximately 4 years
Phase 3: Overall Survival (OS)
Timeframe: Approximately 4 years
Secondary (19)
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Phase 2: Overall Survival (OS)
Phase 2: Number of participants with laboratory abnormalities
Phase 2: Serum concentrations of PF-08634404
Show 14 moreShow less
Phase 2: Incidence of Anti-Drug Antibody (ADA) against PF-08634404
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Phase 3: Number of participants with treatment-emergent adverse events
Phase 3: Number of participants with laboratory abnormalities
Phase 3: Serum concentrations of PF-08634404
Phase 3: Incidence of ADA against PF-08634404
Phase 3: Change from baseline in Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) Total score
Phase 3: Time to definitive deterioration in FACT-Ga Total score
Phase 3: Time to definitive deterioration in Gastric Cancer Subscale (GaCS) score
Arms and interventions
Phase 2 PortionExperimental
PF-08634404 + Chemotherapy
Phase 3: Arm AExperimental
PF-08634404 + Chemotherapy
Phase 3: Arm BActive comparator
Nivolumab + Chemotherapy
Biologicals: PF-08634404, Nivolumab
Drugs: Chemotherapy
Sites
124 sites in 10 countries
United States 102, China 4, Israel 3, Japan 3, Spain 3, Taiwan 3, France 2, Puerto Rico 2, Canada 1, Italy 1